Minerva Neurosciences (NERV)
(Delayed Data from NSDQ)
$2.63 USD
+0.04 (1.54%)
Updated Aug 23, 2024 03:06 PM ET
After-Market: $2.64 +0.01 (0.38%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth C Momentum C VGM
Brokerage Reports
Minerva Neurosciences, Inc [NERV]
Reports for Purchase
Showing records 1 - 20 ( 43 total )
Company: Minerva Neurosciences, Inc
Industry: Medical - Drugs
Awaiting Visibility For Roluperidone''s Path Forward; Decrease PT to $7
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Minerva Neurosciences, Inc
Industry: Medical - Drugs
CRL As Expected; FDA Asks For Additional Study; Maintain Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Minerva Neurosciences, Inc
Industry: Medical - Drugs
CRL Still Most Likely Outcome, In Our View; Phase 1 Trial Offers Hint at Path Forward
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Minerva Neurosciences, Inc
Industry: Medical - Drugs
No Major Updates as PDUFA Approaches; Maintain Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Minerva Neurosciences, Inc
Industry: Medical - Drugs
Boehringer Ingelheim Provides Backstop For Roluperidone; Maintain Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Minerva Neurosciences, Inc
Industry: Medical - Drugs
Lack of AdCom Reduces Chances of Approval; Maintain Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Minerva Neurosciences, Inc
Industry: Medical - Drugs
Minerva Prevails in Dispute Resolution as FDA Accepts NDA for Roluperidone, Though Many Steps Remain; Maintain Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Minerva Neurosciences, Inc
Industry: Medical - Drugs
Fewer Options for Roluperidone to Win Approval; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Minerva Neurosciences, Inc
Industry: Medical - Drugs
We Like Roluperidone But Another Study Looks Necessary; Downgrade to Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Minerva Neurosciences, Inc
Industry: Medical - Drugs
Another Trial Seems Inevitable as FDA Issues RTF; PT Down to $8, Maintain Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Minerva Neurosciences, Inc
Industry: Medical - Drugs
Roluperidone NDA Submitted as Waiting Game Begins; PT Adjusted Down to $24
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Minerva Neurosciences, Inc
Industry: Medical - Drugs
FDA Shows Some Flexibility, But It''s Unclear If That''s Enough for Roluperidone Right Now
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Minerva Neurosciences, Inc
Industry: Medical - Drugs
Preparing for 1H21 Roluperidone Filing; Reiterate Buy; Price Target Lowered to $5
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Minerva Neurosciences, Inc
Industry: Medical - Drugs
FDA Meeting Type Change-up: Detour or Potential Stop Sign for Roluperidone Filing? Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Minerva Neurosciences, Inc
Industry: Medical - Drugs
Roluperidone Shows Bioequivalence Between Formulations and Pre-NDA Meeting Request Planned; Reit Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Minerva Neurosciences, Inc
Industry: Medical - Drugs
Company: Minerva Neurosciences, Inc
Industry: Medical - Drugs
Bioequivalence Study Completes Enrollment as Pre-NDA Activities Continue; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Minerva Neurosciences, Inc
Industry: Medical - Drugs
Positive OLE Data Bolster Confidence in Roluperidone?s Success; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Minerva Neurosciences, Inc
Industry: Medical - Drugs
Roluperidone Phase 3 OLE Shows Continuous Improvement; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Minerva Neurosciences, Inc
Industry: Medical - Drugs
Gathering Additional Data to Build Case for Roluperidone; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D